Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
MD Hellmann, TE Ciuleanu, A Pluzanski…�- …�England Journal of�…, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has�…
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has�…
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1]�…
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1]�…
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or�…
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or�…
[HTML][HTML] Resistance mechanisms to anti-PD cancer immunotherapy
The transformative success of antibodies targeting the PD-1 (programmed death 1)/B7-H1
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However�…
(B7 homolog 1) pathway (anti-PD therapy) has revolutionized cancer treatment. However�…
[HTML][HTML] Immune checkpoint inhibitors: recent progress and potential biomarkers
Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor�…
have the ability to activate different immune checkpoint pathways that harbor�…
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these�…
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these�…
[HTML][HTML] Primary, adaptive, and acquired resistance to cancer immunotherapy
P Sharma, S Hu-Lieskovan, JA Wargo, A Ribas�- Cell, 2017 - cell.com
Cancer immunotherapy can induce long lasting responses in patients with metastatic
cancers of a wide range of histologies. Broadening the clinical applicability of these�…
cancers of a wide range of histologies. Broadening the clinical applicability of these�…
Tumor-infiltrating lymphocytes in the immunotherapy era
ST Paijens, A Vledder, M de Bruyn…�- Cellular & molecular�…, 2021 - nature.com
The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune�…
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune�…
Elements of cancer immunity and the cancer–immune set point
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But
despite the clinical success of antibodies against the immune regulators CTLA4 and PD�…
despite the clinical success of antibodies against the immune regulators CTLA4 and PD�…
Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities
TK Kim, EN Vandsemb, RS Herbst…�- Nature Reviews Drug�…, 2022 - nature.com
Tumours employ various tactics to adapt and eventually resist immune attack. These
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and�…
mechanisms are collectively called adaptive immune resistance (AIR). The first defined and�…